Background: There are many sources of variability in plasma samples drawn for pharmacokinetic analyses or therapeutic drug monitoring. In this article, methods are proposed on how to prevent sample dilution (Part I) and contamination effects (Part II) in plasma samples, using doxorubicin as an example.
INTRODUCTION
Various factors can influence drug concentrations in plasma samples used for pharmacokinetic (PK) analyses or therapeutic drug monitoring (TDM). The sampling site, sampling time, sampling materials, and sample handling play a role, as well as different infusion modalities (eg, type of infusion line, infusion duration, flow rate of drug, and rinsing solution).
The sampling site can play a significant role in the determination of plasma levels of some drugs. In experiments with the local anesthetic bupivacaine, it was found that blood sampling from central veins and arteries provided more reliable and comparable plasma concentrations than peripheral venous sampling. 1 Palm et al 2 found only a small difference between capillary and peripheral venous blood samples from patients who received doxorubicin and judged it to be of minor importance. In a comparison of plasma concentrations from central venous catheters (CVCs) and peripheral veins for various commonly used drugs, there were no clinically significant differences for amikacin, gentamicin, tobramycin, and vancomycin. However, for intravenous cyclosporine, elevated drug concentrations in samples from the CVC were observed. 3 These findings show that the influence of the sampling site should be investigated for each substance individually.
It is also important to consider the impact of the sampling time when interpreting drug concentrations in plasma samples. If it is necessary to measure plasma concentrations of a drug during the infusion, capillary or peripheral venous blood sampling and sampling through a second CVC is preferred. Sampling from the same CVC through which the drug was administered is possible, either by stopping the infusion and taking the blood through the same lumen or through the second lumen in the case of a doublelumen catheter. Problems may occur with either of these approaches. If the infusion is stopped, and if the decrease in plasma concentration is rapid, the measured plasma concentration would be lower than the true value. This is the case with doxorubicin. On the other hand, artificially high plasma concentrations would be detected if the infusion line is not appropriately cleaned before sampling through the same lumen. Even if a second lumen is used, elevated drug concentrations could appear. To our knowledge, Huitema et al 4 are the only authors to have systematically evaluated this kind of sampling when the patient had a Hickman double-lumen catheter with the infusion through a lumen with a distal end and sampling from a lumen with a proximal end.
The material of the infusion lines or sampling tubes can also have an effect on the apparent concentrations in plasma samples used for PK analyses or TDM. Drug adsorption to the infusion line can explain elevated drug concentrations in samples from a CVC used for drug administration. For instance, Shulman et al 3 and Leson et al 5 described the adsorption of cyclosporine to silicone CVCs, and Shader et al 6 described the adsorption of psychotropic drugs to administration sets that contained polyvinylchloride. These observations indicate that the adsorption of a drug to catheter materials needs to be tested for each substance separately.
Especially in infants and very young children, there is a need for further trials because for many drugs, PK data for children are missing. For instance, dosing of cytostatic drugs like doxorubicin is often mainly based on the experience. For PK trials, and also for TDM that is performed for the individual optimization of drug dosing, multiple blood sampling is often unavoidable. Unfortunately, multiple blood sampling is problematic in the pediatric patient group because children have a low blood volume and multiple blood sampling may lead to physical and emotional stress. According to the European Medicines Agency, the trial-related blood loss should not exceed 3% of the total blood volume during a period of 4 weeks and should not exceed 1% at any single time. 7, 8 On these grounds, in pediatric PK trials, the number and the volume of the PK samples are limited to a minimum. Whenever possible, blood samples are taken from the CVC to minimize the number of peripheral venipunctures. Sampling from the CVC carries the risk that samples may be contaminated by the administered drug. To obtain a clean undiluted sample, one of the 3 methods are usually employed: the discard method, 9 the reinfusion method, 10 or the push-pull method. 9 In the discard method, an amount of blood is aspirated into a syringe and is then discarded. The amount of blood discarded varies with hospital practice. Some clinics discard 5 mL or more of blood. This discard volume is recommended by Wanwimolruk et al 11 who postulated flushing a CVC used for digoxin, aminophylline, or phenytoin administration with at least 5 mL of NaCl 0.9 g/dL solution and discarding of 5 mL of blood after the dose administration to avoid artificially elevated drug concentrations in blood samples. In contrast, Cole et al 12 investigated the dilution effect of residual fluid left in different kinds of CVCs or port-a-caths on biochemical and hematological blood samples and postulated that it was enough to discard 3 mL of blood to obtain an accurate blood sample. Also, Odum et al 13 published in 2002 that the withdrawal of 3 mL after initial flushing with 5 mL of saline was sufficient to ensure that the subsequent blood sample is not diluted or contaminated by residual intraluminal fluid. The obvious disadvantage of this method is that a significant volume of blood is discarded in addition to each sample volume. This effect is particularly important in PK trials with frequent blood sampling.
In some clinics, the blood volume is reinfused after the sample is obtained (''reinfusion method''). However, this might lead to blood clots being reinfused or to hemolysis, and there is a potential risk of contamination of the reinfused blood.
A third method is the so-called push-pull method. Here, blood is aspirated into a syringe and reinfused several times without disconnecting the syringe. After the last aspiration/reinfusion cycle, the syringe is disconnected, and a second syringe is used to obtain the required blood sample. This method minimizes the amount of blood wasted and reduces the risk of catheter contamination but still bears the potential for hemolysis. The use of each of these methods varies from one clinic to another, and a change in routine hospital practice is hard to achieve.
Barton et al 9 analyzed the difference between blood obtained after performance of the discard method and the push-pull method in the clinical setting. Blood was obtained with both methods from each patient and was analyzed with regard to hematological parameters and electrolytes. Although statistically significant differences could be identified in some cases, these differences were not clinically significant. A practice change to the push-pull method, especially in pediatric patients to minimize blood loss, was recommended.
In the EU FP7-funded EPOC-MS-001-DOXO-Study, the European Paediatric Oncology Off-Patent Medicines Consortium (EPOC) aims to investigate the age dependency of doxorubicin PK in pediatric patients. With participants from the United Kingdom, France, Germany, and Italy, this multicenter and multinational phase II trial has to deal with a higher degree of variability in terms of PK sampling than would occur with a single center trial. Doxorubicin concentrations will be determined in the plasma of the pediatric study participants. To reduce the variability and the potential mistakes during plasma sampling several aspects play an important role, for instance, the time of sampling due to the drug's fast distribution and accumulation into cells and tissues.
14 Additionally, the handling of the doxorubicin blood samples is crucial. Whole blood containing doxorubicin must be cooled and centrifuged immediately after sampling because of the stability of doxorubicin and metabolism to doxorubicinol in whole blood. According to our investigations, the stability of doxorubicin was limited to 15 minutes when the sample was cooled in an ice-water mixture ab initio.
In the laboratory setting, the influence of sampling technique on the apparent drug concentration in plasma samples was analyzed. The applicability of the push-pull method to clean a CVC filled with isotonic saline solution (NaCl 0.9 g/dL) without dilution of the plasma sample was investigated in vitro (part I). Furthermore, we wanted to develop a cleaning procedure that would prevent plasma sample contamination caused by drug adsorption to the sampling line used for drug administration (part II). Doxorubicin was used as the exemplar drug because it was known to adsorb to materials like, for example, polytetrafluoroethylene, glass, or polyethylene. 15 In the literature, there are no published methods for an adequate cleaning procedure q 2011 Lippincott Williams & Wilkins for doxorubicin blood sampling from a CVC used for drug administration. The ideal method would prevent sample dilution and contamination effects through drug or fluid left in the sampling line.
MATERIALS AND METHODS
High-performance liquid chromatography (HPLC) with fluorescence detection was used to determine doxorubicin and its metabolite doxorubicinol in human plasma in all our experiments. The method was developed based on 2 already published methods 16, 17 The reference compound doxorubicin was provided by Sigma Aldrich Chemie GmbH (Munich, Germany). Doxorubicinol was provided by Chrom Matrix Inc (Richland, WA), and the internal standard epirubicin by the pharmacy of the University Hospital Muenster (UKM) who received the substance from Medac GmbH (Wedel, Germany).
The method was validated according to the criteria of the European Medicines Agency and the Food and Drug Administration. Doxorubicin could be determined in a concentration range of 2-1000 mg/L. The coefficient of determination was higher than 0.98 for all analyses. Furthermore, dilution linearity was demonstrated with correlation coefficients higher than 0.9 and the deviation of the calculated and the nominal concentrations of the solutions was less than 7%. The method fulfilled the criteria for selectivity and reproducibility. Analysis of blank plasma after a sample with a high concentration of doxorubicin did not show any carryover. Nominal and measured values did not deviate more than 10% and 8% at the tested concentrations (less than 20% at the lower limit of quantification), respectively, in investigations of within-run accuracy and between-run accuracy. Intraand interday precision also fulfilled the criterion of a coefficient of variation less than 15% at all tested concentrations. Doxorubicin was stable for 4 days in the extracted sample stored at 220°C. At room temperature, the analyte was stable for 4 hours in the stock solutions. At 220°C and 280°C, stability was demonstrated for 3 months in plasma and for 6 months in the stock solutions. Doxorubicin was stable after 4 cycles of freezing and thawing and after 12.5 hours in an autosampler at room temperature.
Because the stability of doxorubicin was limited to 15 minutes in whole blood and doxorubicin was stable in plasma for 2 hours when stored at room temperature, plasma was used as a substitute for blood due to stability issues in the experiments presented in this article.
Part I: Sample Dilution Experiments
Two types of intravenous access systems were investigated; a port system (port-a-cath from Bard Access Systems with port-needle Ambix Noncor Plus from Fresenius Kabi) and a double-lumen catheter system (from Tyco Healthcare).
We aimed to develop a sampling procedure that would enable hospital personnel to draw doxorubicin plasma samples from a CVC that was filled with NaCl 0.9 g/dL without a dilution effect from the fluid in line. The discard method and the push-pull method were compared. The dead volumes of the port system and the double-lumen catheter system, corresponding to the volume of the line when completely filled with NaCl 0.9 g/dL solution, were measured. For the port system, the dead volume was 0.9 mL, and for the doublelumen catheter system, it was 1 mL.
For the sample dilution experiments, both systems were filled with NaCl 0.9 g/dL. Predefined volumes of a doxorubicin plasma solution with a concentration of 750 mg/L were drawn through each system into a syringe. In the discard method, volumes corresponding to 1.5, 2, 3, and 4 dead volumes were drawn up and discarded. Then, a sample of 500 mL of plasma was drawn into a new syringe. In the push-pull method, volumes corresponding to 2 and 4 dead volumes were aspirated into a syringe and reinfused 5 times. Assuming that when performing the push-pull method in a patient, the patient's blood flow would distribute the plasma reinfused very quickly in the body, the plasma that was pushed back was discarded at each time and a fresh plasma solution containing doxorubicin was pulled up in the next step. After the last aspiration/reinfusion cycle, the syringe was disconnected and a new syringe was used to obtain the required plasma sample of 500 mL through each system, port system or double-lumen catheter system. Each in vitro experiment was performed in triplicate, and the doxorubicin concentrations of the plasma samples were determined by HPLC and fluorescence detection in duplicate.
Part II: Sample Contamination Experiments
We aimed to develop a cleaning procedure for clinical practice to avoid contamination effects in plasma samples, using doxorubicin as an example. These effects could arise through drug adsorption to the catheter used to administer the drug. The doxorubicin solution was provided by the pharmacy of the UKM in a typical, clinically used concentration (1 mg/mL of doxorubicin in glucose 5%).
Determination of the NaCl 0.9 g/dL Volume Necessary to Clean the Infusion Line After Drug Administration
In the first experiment, it was aimed to determine the concentration of the solution left in the infusion line after rinsing with different volumes of NaCl 0.9 g/dL rinsing solution. Therefore, an infusion system with a dead volume of 8 mL was assembled according to clinical practice in the UKM. The system was composed of a Perfusor secura FT syringe driver, an original Perfusor infusion tube, and a Discofix 3-gang manifold, all three provided by B. Braun Melsungen AG (Melsungen, Germany), an Ambix Noncor Plus port-needle from Fresenius Kabi AG (Bad Homburg vor der Höhe, Germany), and a port-a-cath from Bard Access Systems, Inc (Salt Lake City, UT). The infusion line was filled with a 1 mg/mL of doxorubicin solution. Then, rinsing with NaCl 0.9 g/dL solution with a flow rate of 50 mL per hour was initiated. Samples of 500 mL were taken at predefined times from the port end of the infusion line.
Determination of the Plasma Volume Necessary to Clean the Sampling Line Before PK Sampling Through the Catheter Used for Drug Administration
We aimed to determine the NaCl 0.9 g/dL rinsing volume and the plasma discard volume necessary to obtain a sample free of contamination through a CVC used for drug administration. Therefore, the system was filled with a 0.3 mg/mL of doxorubicin solution. Then, the doxorubicin solution was disconnected, and the NaCl 0.9 g/dL solution was connected to the infusion line. Rinsing was initiated with a flow rate of 50 mL per hour for either 2 or 4 dead volumes of the infusion line. After this rinsing procedure, the infusion line was disconnected from the port system. On working only with this sampling line, a volume of 3.6 mL blank plasma, corresponding to 4 dead volumes of the sampling line, was drawn from the patient's end of the line through the port system into a syringe. This syringe with the plasma was discarded. Then, a sample of 500 mL plasma was drawn into a new syringe in the same manner. Each experiment was performed in triplicate, and the doxorubicin concentrations of the plasma samples were determined by HPLC measurement and fluorescence detection in duplicate.
RESULTS

Part I: Sample Dilution Experiments
To obtain a plasma sample without dilution from an intravenous port system or double-lumen catheter system, 2 different sampling procedures were investigated. With the discard method, drug concentrations were approximately 90% of the initial value after discarding a plasma volume that corresponded to 1.5 dead volumes of the system, for both the port system and the double-lumen catheter system. However, the optimal volume with the discard method was 4 dead volumes of the sampling line, corresponding to 3.6 and 4 mL for the port system and the double-lumen catheter system, respectively. With this discard volume, the concentration of doxorubicin in the samples was nearly 100% of the initial value. However, discarding this volume of blood before each blood sample is often not suitable, especially when multiple sampling is scheduled in infants and small children. For this patient group, the push-pull method could present an alternative because with this method, no blood is lost. Using the push-pull method with only 2 sampling line dead volumes resulted in sample dilution, the measured value being only approximately 80% of the initial doxorubicin concentration. However, by pulling up and down 5 times a volume of plasma corresponding to 4 sampling line dead volumes, the concentration of doxorubicin in the samples obtained was nearly 100% of the initial value (Fig. 1) . Therefore, when using 4 sampling line dead volumes, the push-pull method was a good alternative to the discard method with no need to waste blood.
Part II: Sample Contamination Experiments
Determination of the NaCl 0.9 g/dL Volume Necessary to Clean the Infusion Line After Drug Administration
The aim of this experiment was to determine the volume of NaCl 0.9 g/dL rinsing solution and the time necessary to clean the infusion line filled with a doxorubicin solution with a concentration often used in clinical practice. Even after more than 60 minutes of rinsing with a volume of NaCl 0.9 g/dL that corresponded to 6.5 dead volumes of the infusion line, a doxorubicin concentration greater than 250 mg/L could be detected in the rinsing solution (Fig. 2) .
Determination of the Plasma Volume Necessary to Clean the Sampling Line Before PK Sampling Through the Catheter Used for Drug Administration
This experiment aimed to determine a practicable cleaning procedure for clinical practice to obtain plasma sample without contamination from the CVC used for drug administration. Therefore, a sample was drawn after rinsing the infusion system with 16 mL of NaCl 0.9 g/dL solution (corresponding to 2 dead volumes of the infusion system) and after using the discard method with 4 sampling line dead volumes.
Under these conditions, the measured concentration of doxorubicin was between 44 and 184 mg/L (mean, 98 mg/L; median, 65 mg/L). This is in a concentration range that could significantly influence the measurement of doxorubicin in clinical practice. Peak plasma concentrations are usually between 100 and 1000 mg/L. Therefore, the experiments were repeated in a modified way. Rinsing of the infusion line was performed with a NaCl 0.9 g/dL volume of 32 mL (corresponding to 4 dead volumes of the infusion system), and afterward, the discard method with 4 sampling line dead volumes was performed. With this method, the concentration was less than 5 mg/L. This concentration would have a negligible influence on a doxorubicin plasma sample obtained for PK analysis.
DISCUSSION
There are several reports in the literature concerning blood sampling through the catheter used for drug administration. In 1999, Cash et al 18 and in 2007, Ritzmo et al 19 described methotrexate sampling through a CVC used for drug administration in oncological pediatric patients as concluded that blood sampling through a CVC used for infusion of 2-deoxy-2-[18F]-fluoro-glucose provided drug concentrations that were only insignificantly overestimated compared with concentrations in samples taken from a second CVC through which drug was not administered. Contrary examples of higher than expected concentrations in samples drawn through a CVC used for drug administration have been reported for phenytoin, 21 tacrolimus, 22, 23 and vancomycin. 24 Significant differences were found in tobramycin levels between samples drawn after 1 and 3 hours after drug administration from the same CVC or from peripheral veins, despite flushing with 5 mL of NaCl 0.9 g/dL solution and discarding of 5 mL of blood before sampling. 25 Similar effects were also observed for serum gentamicin concentrations in samples drawn either peripherally or through the drug administration CVC after a blood discard volume of 5 mL. 26 In particular, these authors viewed port-a-caths as unsuitable for monitoring gentamicin. These findings indicate that sampling through a CVC used for drug administration could influence drug concentrations in plasma samples if the appropriate flushing method was not applied.
In a recent publication, Skolnik et al 27 investigated the best catheter cleaning method in in vitro analyses using actinomycin-D and vincristine as model drugs. The authors evaluated the effects of flush volume, composition, and pH of rinsing solution and the number of blood-draw return cycles on residual drug concentrations. They observed lower propensity for catheter adsorption for vincristine as for actinomycin-D. Furthermore, they reported that complete removal of drug from the catheter was obtained for both substances after 5 blood-draw return cycles consisting of 5 mL of whole blood. In their experimental design, they focused on adsorption effects of the drug to the catheter. A second source of error that can influence drug concentration in plasma samples taken from a CVC is dilution of the samples by liquid in the catheter before obtaining the sample. This aspect was not investigated in their study. Neither could we find any other publication that investigated the dilution effect in vitro.
In the first set of experiments, we therefore focused on dilution effects. We first determined the volume to be discarded before obtaining an undiluted sample. For the port system, a discard volume of 3.6 mL and for the double-lumen catheter system, a discard volume of 4 mL, corresponding to a volume equal to 4 dead volumes of the sampling lines, were necessary to obtain an undiluted doxorubicin sample. Those volumes are slightly higher than the discard volume of 3 mL postulated by Cole et al, 12 but Cole performed the investigations in the clinical setting with different types of catheters for which dead volumes varied from 0.15 to 2.3 mL. Consideration of the dead volume of the catheter and line to the point where sampling is performed and minimizing this by avoiding any extra line or stopcock is from our point of view essential when deciding about the discard volume.
A good alternative to the discard method with no need to waste blood proved to be pulling up and down 5 times this volume of plasma before taking a sample. Especially for small children and infants, this should be the preferred method to reduce blood loss. Furthermore, this method can also be used in PK trials or TDM for all patients, including adults, for whom blood loss is not the problem, to reduce preanalytical errors arising from absorption of the drug to the catheter line, as shown by Skolnik et al. 27 In the second set of experiments, we aimed to identify an adequate cleaning procedure for doxorubicin plasma sampling through a CVC used for drug administration, providing a sample that was neither diluted nor contaminated. Rinsing by infusion over 1 hour with NaCl 0.9 g/dL solution after doxorubicin infusion left residual doxorubicin concentrations greater than 250 mg/L. This level of contamination would provide a significantly false-value for a PK sample. Therefore, a standardized procedure was needed to ensure a clean sampling line before doxorubicin plasma sampling. In the experiments, after rinsing the infusion line with a volume of NaCl 0.9 g/dL solution that corresponded to 4 dead volumes of the infusion system, and after applying the discard method with a volume corresponding to 4 dead volumes of the sampling line, the doxorubicin concentration in the plasma sample was negligibly small. To shorten the rinsing time and the surface for drug administration, it is possible and recommended to reduce the dead volume of the infusion system.
CONCLUSIONS
Our results and those of previously published articles show the need for the development of specific cleaning procedures to obtain undiluted and uncontaminated plasma samples for PK analyses and TDM. We showed that the pushpull method was an adequate alternative to the discard method with no need to waste blood. For the experimental setting, an appropriate cleaning procedure was found for doxorubicin plasma sampling through the drug administration catheter. In this cleaning procedure, we would recommend an adequate NaCl 0.9 g/dL rinsing volume and a plasma volume to be discarded or pulled up and down before doxorubicin plasma sampling. These results and suggestions for a cleaning procedure for doxorubicin may be transferable to many but not all other drugs. For drugs known to have a high degree of adsorption to plastics, for instance, it is recommended that specific cleaning procedures need to be developed in a fashion analogous to that employed here.
